These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17290298)

  • 1. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac regulation by phosphoinositide 3-kinases and PTEN.
    Oudit GY; Penninger JM
    Cardiovasc Res; 2009 May; 82(2):250-60. PubMed ID: 19147653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
    Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
    Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies.
    Harris SJ; Foster JG; Ward SG
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1151-62. PubMed ID: 19876783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis.
    Reedquist KA; Ludikhuize J; Tak PP
    Biochem Soc Trans; 2006 Nov; 34(Pt 5):727-30. PubMed ID: 17052183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocytes on the move with phosphoinositide 3-kinase and its downstream effectors.
    Procko E; McColl SR
    Bioessays; 2005 Feb; 27(2):153-63. PubMed ID: 15666353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do phosphoinositide 3-kinases direct lymphocyte navigation?
    Ward SG
    Trends Immunol; 2004 Feb; 25(2):67-74. PubMed ID: 15102365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.
    Weichhart T; Säemann MD
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease.
    Marwick JA; Chung KF; Adcock IM
    Ther Adv Respir Dis; 2010 Feb; 4(1):19-34. PubMed ID: 20051446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PI3K in immune cells.
    Koyasu S
    Nat Immunol; 2003 Apr; 4(4):313-9. PubMed ID: 12660731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines in the pathogenesis of rheumatoid arthritis.
    McInnes IB; Schett G
    Nat Rev Immunol; 2007 Jun; 7(6):429-42. PubMed ID: 17525752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity.
    Paunovic V; Carroll HP; Vandenbroeck K; Gadina M
    Rheumatology (Oxford); 2008 Jun; 47(6):771-6. PubMed ID: 18238793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-lymphocyte navigation and migration: beyond the PI3K paradigm.
    Smith L; Webb A; Ward SG
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):193-8. PubMed ID: 17371236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting signaling pathways with small molecules to treat autoimmune disorders.
    Kaminska B; Swiatek-Machado K
    Expert Rev Clin Immunol; 2008 Jan; 4(1):93-112. PubMed ID: 20477590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.